V. Richter: "The low toxicity and originality of the pharmaceutical agent are its major advantages"

V. A. Richter; Рихтер В. А.

doi:10.32607/20758251-2012-4-1-9-11

V. Richter: "The low toxicity and originality of the pharmaceutical agent are its major advantages"

Authors: Richter V.A.¹
Affiliations:
1. Institute of Chemical Biology and Fundamental Medicine, SB RAS
Issue: Vol 4, No 1 (2012)
Pages: 9-11
Section: Forum
Submitted: 17.01.2020
Published: 15.03.2012
URL: https://actanaturae.ru/2075-8251/article/view/10627
DOI: https://doi.org/10.32607/20758251-2012-4-1-9-11
ID: 10627

Cite item

Full Text

Abstract
About the authors
References
Supplementary files
Statistics

Abstract

There is no question that the government needs to provide vigorous financial support to Russian researchers looking to design new drugs. A different question is to what extent should the government participate in the financing and at
what point should industrial investors join in?